November 27, 2018
Julca Combination approved in Japan for treating HIV
ViiV Healthcare and Janssen Sciences Ireland UC’s Juluca Combination Tablets for treating HIV (type 1) was approved by the Ministry…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 27, 2018
Sandoz gets marketing pass in EU for Ziextenzo, for helping treat cancer with cytotoxic chemotherapy in adults
Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…
November 23, 2018
EU approves Novartis’ the one-time gene therapy Luxturna
Novartis’ Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation, developed…
November 23, 2018
Curetis nears clearing BAL as additional sample type for Unyvero LRT
The U.S. FDA confirmed that data required for the submission can largely be based on clinical samples previously collected during…
November 22, 2018
Oasmia’s Apalea approved in Europe for ovarian cancer
After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…
November 22, 2018
GSK, Kyowa Hakko Kirin mutual work on potential oral treatment for CKD related anaemia
GSK and Kyowa Hakko Kirin will together commercialize in Japan the treatment of chronic kidney disease related anaemina, which GKS…
November 21, 2018
Sandoz, Pear Therapeutics launch reSET for patients with Substance Use Disorder
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…
November 21, 2018
Indivior trusts its portfolio, aware of challenges for Suboxone
Indivior PLC said Wednesday said in a statement it is dissapointed by the US District Court for the District of…
November 20, 2018
Swedish Oasmia Pharmaceutical’s nanotechnology platform XR17 patented in USA
Swedish Oasmia Pharmaceutical said on Tuesday that it got a patent for its unique nanotech method to produce novel pharmaceutical formulations, from the United States Patent and Trademark Office (USPTO).
November 20, 2018
Denali Therapeutics’ RIPK1 inhibitor molecule shows well in clinical test
Denali Therapeutics, a neurodegenerative diseases specialist, on Tuesday brought to public positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1),